Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 4:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 20,694 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Peripheral Blood Clear all

Conditions: Abnormal Vascular Flow
Interventions: Umbilical Cord Milking, Immediate Cord Clamping; Procedure
Lead sponsor: Sharp HealthCare; Other
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: San Diego, California

Conditions: Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
Interventions: bendamustine, rituximab, vincristine, prednisone, cyclophosphamide, doxorubicin; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 79
States / cities: Tucson, Arizona • Little Rock, Arkansas • Corona, California + 70 more

Conditions: Puberty, Hyperandrogenism
Interventions: Blood sampling; Other
Lead sponsor: University of Virginia; Other
Eligibility: 7 Years to 17 Years · Female only
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Lymphoma
Interventions: rituximab, bortezomib, pegylated liposomal doxorubicin hydrochloride, gene expression analysis, polymerase chain reaction, polymorphism analysis, proteomic profiling, flow cytometry, laboratory biomarker analysis; Biological · Drug · Genetic + 1 more
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Alcohol Abuse
Interventions: Brief Motivational Intervention (BMI), Substance-Free Activity Session (SFAS), Relaxation Session; Behavioral
Lead sponsor: University of Memphis; Other
Eligibility: 18 Years to 27 Years
Enrollment: 393 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Columbia, Missouri • Memphis, Tennessee

Conditions: Lung Cancer
Interventions: filgrastim, paclitaxel, topotecan hydrochloride; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 19
States / cities: Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 16 more

Conditions: Obesity, Hypertension, Circadian Dysregulation, Salt; Excess
Interventions: Oral sodium supplementation; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 25 Years to 45 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Chronic Lymphocytic Leukemia (CLL)
Interventions: Obinutuzumab, Venetoclax, Fludarabine, Cyclophosphamide, Rituximab, Bendamustine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 4
States / cities: Aurora, Colorado • Bethesda, Maryland • Knoxville, Tennessee + 1 more

Conditions: Colorectal Neoplasms
Interventions: Blood draw; Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 29
States / cities: Mobile, Alabama • Tucson, Arizona • Fresno, California + 26 more

Conditions: Urethritis, Healthy Men Age 18-50 With no Urethral Symptoms
Interventions: Colli-Pee, standard of care 60 mL urine cup, Urinalysis, Sysmex UP-5000; Device · Diagnostic Test
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Therapeutic Adherence and Compliance
Interventions: Feedback on DBS Concentrations; Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease, Huntington's Disease, Amyotrophic Lateral Sclerosis (ALS)
Interventions: Not listed
Lead sponsor: Sanguine Biosciences; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Sherman Oaks, California

Conditions: Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Lymphoblastic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, t(9;22)
Interventions: Dexamethasone, Ponatinib Hydrochloride, Rituximab, Venetoclax; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neoplasms
Interventions: EZN-2208, Bevacizumab; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Parkinson Disease
Interventions: Lumbar Puncture; Procedure
Lead sponsor: Michael J. Fox Foundation for Parkinson's Research; Other
Eligibility: 30 Years and older
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Chicago, Illinois • New York, New York • Portland, Oregon + 1 more

Conditions: Prostate Cancer
Interventions: sipuleucel-T; Biological
Lead sponsor: Dendreon; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 12
States / cities: La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 5 more

Conditions: Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Lutetium Lu 177 Vipivotide Tetraxetan, Cell-free Circulating Tumor DNA Assay, Computed Tomography, Docetaxel, PSMA PET Scan, Single Photon Tomography and Computed Tomography Scan, Biospecimen Collection; Drug · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Shared Neoantigen-Positive Solid Tumors
Interventions: GRT-C903, GRT-R904, nivolumab, ipilimumab; Biological
Lead sponsor: Gritstone bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 12
States / cities: Phoenix, Arizona • Santa Monica, California • Jacksonville, Florida + 8 more

Conditions: Hypovitaminosis D
Interventions: Vitamin D3, Calcium, and Vitamin C; Dietary Supplement
Lead sponsor: Atlantic Health System; Other
Eligibility: 6 Years to 21 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Morristown, New Jersey

Conditions: Primary Immunodeficiency
Interventions: Gadolinium For abdomen, Gadolinium For lower back, Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, Efficacy of Gammagard subcutaneously at Week 36, Efficacy of Gammagard subdermally at Week 36, Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, Adverse Reactions of Gammagard subcutaneously at Week 36, Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, Adverse Reactions of Gammagard subdermally at Week 36; Drug
Lead sponsor: ASIS Corporation; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Westminster, California

Conditions: Hepatorenal Syndrome, Renal Failure, Liver Diseases
Interventions: Blood Draws and a hepatectomy specimen, Blood draw - pre operative standard of care; Procedure
Lead sponsor: Lahey Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Ultraviolet Light Burn
Interventions: Ultra Violet Light Exposure; Other
Lead sponsor: Access Business Group; Industry
Eligibility: 20 Years to 50 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Glioblastoma, IDH-Wildtype, WHO Grade 4 Glioma
Interventions: Best Practice, Biospecimen Collection, Dietary Intervention, Glucose Measurement, Magnetic Resonance Imaging, Monitoring, Questionnaire Administration, Supportive Care; Other · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Salivary Gland Cancer, HER2 Gene Mutation
Interventions: Ado-trastuzumab (T) emtansine (T-DM1), Standard of Care Radiotherapy, Standard of Care Chemotherapy; Drug · Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 13
States / cities: Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 8 more

Search by objective public record fields.

Effects of Milking the Umbilical Cord on Systemic Blood Flow

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

Assessment of Day-night Secretion of Progesterone and LH Across Puberty

Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment

Improving Brief Alcohol Interventions With a Behavioral Economic Supplement

Topotecan, Paclitaxel, and Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer

Timing of Sodium Intake and Nocturnal Sodium Excretion and Blood Pressure in Obese African Americans

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

Pharmacogenomics Blood Sampling Protocol For Irinotecan/Fluorouracil/Leucovorin(CPT-11/FU/LV).

Establishing Baseline Sysmex UF-5000 Flow Cytometer Results in Healthy Men

Use of Antiretroviral (ARV) Drug Levels in Dried Blood Spots (DBS) to Assess and Manage ART Adherence in South Africa

A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery

Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors

FoxBioNet: ECV (Extracellular Vesicle) 004

To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen

Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial

A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens

The Effectiveness of a Weight-dependent Algorithm for Dosing Vitamin D.

ASIS for GAMMAGARD in Primary Immunodeficiency

Role Of Angiogenic Factors In The Development Of Hepatorenal Syndrome

Molecular Responses Caused by UV Exposure of Human Skin

Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas